Cambrex, a prominent global contract development and manufacturing organization (CDMO), has recently augmented its peptide manufacturing capabilities through its subsidiary Snapdragon Chemistry located in Waltham, Massachusetts. This expansion aims to bolster the support for the development and production of peptide therapies within the pharmaceutical industry. The newly added GMP manufacturing suite, with an ISO-7 cleanroom, facilitates preparative HPLC chromatography, lyophilization, cold storage for raw materials, and a product storage suite. Snapdragon Chemistry’s investment in this facility enables the seamless progression of peptide projects from development to GMP manufacturing, utilizing solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid methodologies.
Dr. Eric Fang, the General Manager at Snapdragon Chemistry, outlined the three-step strategy employed in the development of peptide drug candidates within the new facility. The process commences with automated SPPS technology for proof-of-concept, followed by the optimization of the process using LPPS technology to enhance efficiency and reduce manufacturing costs. Subsequently, the finalized process can be transferred to larger manufacturing facilities such as the one in Charles City, Iowa, for mass production using traditional large batch reactors, thereby significantly reducing the overall drug costs. The LPPS technology integrated by Snapdragon Chemistry combines the use of traditional API batch reactors and continuous flow techniques, reducing solvent demand and minimizing the requirement for excess reagents compared to conventional solid-state peptide synthesis methods.
While SPPS technology is crucial for rapid development and proof-of-concept in the initial stages, it may not be a scalable solution for mass production to cater to a large patient population. Dr. Matt Bio, Chief Scientific Officer at Cambrex, emphasized the importance of the LPPS process, designed to leverage Cambrex’s substantial capacity to deliver peptide therapies efficiently. The company’s continued investment in research and development focuses on enhancing peptide manufacturing processes and exploring the application of artificial intelligence to optimize oligonucleotide processes. Snapdragon Chemistry, a subsidiary of Cambrex, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing cutting-edge automation technology and proprietary equipment to address complex process and analytical challenges effectively.
Cambrex, as a leading global CDMO with over 40 years of experience and a team of 2,000 experts servicing clients worldwide, offers a comprehensive range of drug substance development and manufacturing services across the drug lifecycle. The company’s specialized capabilities encompass various technologies such as continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. The recent expansion in peptide manufacturing capabilities in Waltham, Massachusetts, signifies Cambrex’s commitment to advancing pharmaceutical manufacturing processes and meeting the evolving needs of the industry.
- Snapdragon Chemistry’s investment in a new GMP manufacturing suite in Massachusetts enhances support for peptide therapies.
- The three-step strategy employed in peptide drug development includes automated SPPS technology for proof-of-concept and LPPS technology for optimization.
- Cambrex’s focus on enhancing peptide manufacturing processes and exploring AI applications underlines its commitment to innovation in pharmaceutical development.
- The integration of LPPS technology by Snapdragon Chemistry reduces solvent demand and enhances manufacturing efficiency compared to traditional methods.
Tags: automation, lyophilization, process development, chromatography
Read more on taiwannews.com.tw